ReviewJournal of cancer research and clinical oncology2025
De Novo MET-amplified NSCLC treated with savolitinib achieved remarkable tumor regression: a case report and review of literature.
Jin Sheng et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.